What is DeepScribe?
DeepScribe is a technology company offering a dual-solution platform designed to enhance patient encounters and streamline documentation. Its Telemedicine Platform provides remote access for patient consultations, automatically documenting each interaction. This integrated approach addresses critical needs in healthcare delivery, particularly in the evolving landscape of remote patient care and administrative efficiency.
How much funding has DeepScribe raised?
DeepScribe has raised a total of $35.2M across 2 funding rounds:
Angel/Seed
$5.2M
Unspecified
$30M
Angel/Seed (2021): $5.2M with participation from Skydeck, Foothill Ventures, Industry Ventures, Plug and Play Tech Center, Sequoia Scout Fund, Supernode Ventures, Wavemaker Three-Sixty Health, Stage 2 Capital, and 1984 Ventures
Unspecified (2022): $30M led by Stage 2 Capital, 1984 Ventures, Index Ventures, and Bee Partners
Key Investors in DeepScribe
Stage 2 Capital
Stage 2 Capital is a venture capital fund that leverages a vast network of over 800 go-to-market experts to invest in B2B software companies. They focus on providing operational expertise and data-driven frameworks to help portfolio companies achieve product-market fit and scale revenue.
1984 Ventures
1984 Ventures is a venture capital firm established in 2018, specializing in seed and early-stage startup investments. The company is headquartered in San Francisco, California, and focuses on identifying promising new ventures.
Index Ventures
Index Ventures is a global venture capital firm that partners with entrepreneurs from seed to IPO. They invest in companies with bold visions, supporting founders in building enduring businesses across various sectors.
What's next for DeepScribe?
The substantial enterprise-level funding indicates DeepScribe is poised for significant scaling and market expansion. Future strategic initiatives will likely focus on enhancing its AI-driven documentation capabilities, broadening its Telemedicine reach, and potentially exploring new healthcare verticals. This capital infusion will empower the company to further innovate and solidify its competitive advantage in the health-tech sector.
See full DeepScribe company page
